Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012696 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Haochi Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Reproductive Regulation & Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, P.R. C…. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Infections, Polysaccharides, Bacterial, Immunity, Mucosal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Major Project of the Inner Mongolia Autonomous Region of China, Education Department of Inner Mongolia Autonomous Region, National Natural Science Foundation of China.
Abstract (Originalsprache)
Respiratory infections caused by Pseudomonas aeruginosa are a major health problem globally. Current treatment for P . aeruginosa infections relies solely on antibiotics, but the rise of antibiotic-resistant strains necessitates an urgent need for a protective vaccine. Traditional parenteral vaccines, despite employing potent adjuvants aimed at serotype-dependent immunity, often fail to elicit the desired mucosal immune response. Thus, developing vaccines that target both localized mucosal and systemic immune responses represents a promising direction for future research on P . aeruginosa vaccination. In this study, we explored EPS301, the exopolysaccharide derived from the lung microbiota strain Lactobacillus plantarum WXD301, which exhibits excellent self-assembly properties, enabling the formation of homogeneous nanoparticles when encapsulating recombinant PcrV of P . aeruginosa , designated as EPS301@rPcrV. Notably, the EPS301 vector effectively enhanced antigen adhesion to the nasal and pulmonary mucosal tissues and prolonged antigen retention. Moreover, EPS301@rPcrV provided effective and sustained protection against P . aeruginosa pneumonia, surpassing the durability achieved with the "gold standard" cholera toxin adjuvant. The EPS301-adjuvanted vaccine formulation elicited robust mucosal IgA and Th17/γδ17 T cell responses, which exceeded those induced by the CTB-adjuvanted vaccination and were sustained for over 112 days. Additionally, Th 17 and γδ 17 resident memory T cells induced by EPS301@rPcrV were crucial for protection against P . aeruginosa challenge. Intriguingly, IL-17A knockout mice exhibited lower survival rates, impaired bacterial clearance ability, and exacerbated lung tissue damage upon EPS301 adjuvanted vaccination against P . aeruginosa -induced pneumonia, indicating an IL-17A-dependent protective mechanism. In conclusion, our findings provided direct evidence that EPS301@rPcrV mucosal vaccine is a promising candidate for future clinical application against P . aeruginosa -induced pulmonary infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Reproductive Regulation & Breeding of Grassland Livestock, School of Life Sciences, Inner Mongolia University, Hohhot, P.R. China.
- The Spirit Jinyu Biological Pharmaceutical Co. Ltd, Hohhot, Inner Mongolia, China.
ORCID-Profile: Xiao Wang
Förderung
- Science and Technology Major Project of the Inner Mongolia Autonomous Region of China
- Education Department of Inner Mongolia Autonomous Region
- National Natural Science Foundation of China
- Technology Major Project of Hohhot
- Postdoctoral Research Foundation of China
Zitieren
APA
Zhang, H., Sheng, S., Li, C., Bao, X., Zhao, L., Chen, J., Guan, P., Li, X., Pan, N., Liang, Y., Wang, X., Sun, J., & Wang, X. (2024). Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012696
Vancouver
Zhang H, Sheng S, Li C, Bao X, Zhao L, Chen J, et al. Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012696
BibTeX
@article{Zhang2024,
author = {Zhang, Haochi and Sheng, Shouxin and Li, Chunhe and Bao, Xuemei and Zhao, Lixia and Chen, Jian and Guan, Pingyuan and Li, Xiaoyan and Pan, Na and Liang, Yanchen and Wang, Xueqi and Sun, Jingmin and Wang, Xiao},
title = {Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012696}
}
EUVIMED